GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Sunzen Biotech Bhd (XKLS:0148) » Definitions » Cyclically Adjusted Revenue per Share

Sunzen Biotech Bhd (XKLS:0148) Cyclically Adjusted Revenue per Share : RM0.31 (As of Sep. 2023)


View and export this data going back to 2008. Start your Free Trial

What is Sunzen Biotech Bhd Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Sunzen Biotech Bhd's adjusted revenue per share for the three months ended in Sep. 2023 was RM0.036. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is RM0.31 for the trailing ten years ended in Sep. 2023.

During the past 12 months, Sunzen Biotech Bhd's average Cyclically Adjusted Revenue Growth Rate was 3.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2024-05-16), Sunzen Biotech Bhd's current stock price is RM0.365. Sunzen Biotech Bhd's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2023 was RM0.31. Sunzen Biotech Bhd's Cyclically Adjusted PS Ratio of today is 1.18.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sunzen Biotech Bhd was 1.19. The lowest was 0.56. And the median was 0.77.


Sunzen Biotech Bhd Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Sunzen Biotech Bhd's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunzen Biotech Bhd Cyclically Adjusted Revenue per Share Chart

Sunzen Biotech Bhd Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.26 0.28 0.30

Sunzen Biotech Bhd Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.30 0.30 0.31 0.31

Competitive Comparison of Sunzen Biotech Bhd's Cyclically Adjusted Revenue per Share

For the Packaged Foods subindustry, Sunzen Biotech Bhd's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunzen Biotech Bhd's Cyclically Adjusted PS Ratio Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Sunzen Biotech Bhd's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sunzen Biotech Bhd's Cyclically Adjusted PS Ratio falls into.



Sunzen Biotech Bhd Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Sunzen Biotech Bhd's adjusted Revenue per Share data for the three months ended in Sep. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Sep. 2023 (Change)*Current CPI (Sep. 2023)
=0.036/129.8595*129.8595
=0.036

Current CPI (Sep. 2023) = 129.8595.

Sunzen Biotech Bhd Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201312 0.045 98.326 0.059
201403 0.033 99.695 0.043
201406 0.035 100.560 0.045
201409 0.030 100.428 0.039
201412 0.037 99.070 0.048
201503 0.028 99.621 0.036
201506 0.031 100.684 0.040
201509 0.018 100.392 0.023
201512 0.022 99.792 0.029
201603 0.023 100.470 0.030
201606 0.026 101.688 0.033
201609 0.019 101.861 0.024
201612 0.024 101.863 0.031
201703 0.090 102.862 0.114
201706 0.144 103.349 0.181
201709 0.144 104.136 0.180
201712 0.192 104.011 0.240
201803 0.147 105.290 0.181
201806 0.104 106.317 0.127
201809 0.202 106.507 0.246
201812 0.137 105.998 0.168
201903 0.127 107.251 0.154
201906 0.133 108.070 0.160
201909 0.118 108.329 0.141
201912 0.085 108.420 0.102
202003 0.040 108.902 0.048
202006 0.024 108.767 0.029
202009 0.038 109.815 0.045
202012 0.053 109.897 0.063
202103 0.045 111.754 0.052
202106 0.038 114.631 0.043
202109 0.027 115.734 0.030
202112 0.047 117.630 0.052
202203 0.044 121.301 0.047
202206 0.040 125.017 0.042
202209 0.033 125.227 0.034
202212 0.017 125.222 0.018
202303 0.031 127.348 0.032
202306 0.027 128.729 0.027
202309 0.036 129.860 0.036

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Sunzen Biotech Bhd  (XKLS:0148) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sunzen Biotech Bhd's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.365/0.31
=1.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Sunzen Biotech Bhd was 1.19. The lowest was 0.56. And the median was 0.77.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Sunzen Biotech Bhd Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Sunzen Biotech Bhd's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunzen Biotech Bhd (XKLS:0148) Business Description

Traded in Other Exchanges
N/A
Address
No. 11, Jalan Anggerik Mokara 31/47, Kota Kemuning, Shah Alam, SGR, MYS, 40460
Sunzen Biotech Bhd is engaged in the business of research and development of biotechnology and manufacturing and marketing of animal health products. The company operates in the business segments of Manufacturing and trading animal health products; Trading and processing of crude palm oil and related products; Traditional Chinese medicines and herbal health foods and beverages and loan financing. It generates key revenue from the Traditional Chinese medicines and herbal health foods and beverages segment.

Sunzen Biotech Bhd (XKLS:0148) Headlines

No Headlines